Press release originally published May 17, 2022 on Avrobio.com. New early data show key visual motor integration, visual perception...
Read moreBy Cystinosis Research Network
May 17, 2022
A global initiative has been announced: the Cystinosis Warrior Impact Program. Our goal is to support, help or find...
Read moreBy Cystinosis Research Network
April 29, 2022
Leadiant, the makers of Cystaran eye drops, are opening up the floor for a Town Hall Q&A on Wednesday,...
Read moreBy Cystinosis Research Network
April 20, 2022
The Neuromuscular Clinic at Massachusetts General Hospital (MGH) led by Dr. Reza Seyedsadjadi, is currently enrolling participants for a...
Read moreEmory University in Atlanta, Georgia, is actively recruiting for the Cohort 0 control groupin the CYStem clinical trial. While...
Read moreA new chapter in cystinosis research has begun. Novartis has officially opened the next phase of its CYStem Phase...
Read moreFor our families using Cystadrops, we received the following information from Recordati. This update was in response to direct...
Read moreNovartis has announced the Phase I/II CYStem clinical trial will recruit children ages 2-5 with nephropathic cystinosis. The trial...
Read moreThe CRN-funded QUALIFY-US study, also known as the Quality of Life study, is wrapping up this month. Our researchers...
Read more